Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive Advanced Kinase Inhibitor Naive RET-Mutant Medullary Thyroid Cancer
Brief description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
thyroid cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
10 Jun 2020.
Study ID: 834733
